Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services July 14 released its calendar year 2026 proposed rule for the physician fee schedule. As required by…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The Rural Hospital Excellence in Innovation Award honors rural hospitals that are leading the way in innovative, sustainable and community-centered care. If…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The Centers for Medicare & Medicaid Services June 30 issued its calendar year 2026 proposed rule for the home health prospective payment system. This rule…